Production of tissue-engineered intestine from expanded enteroids

Area of Science:

• Regenerative Medicine
• Gastroenterology
• Biomaterials Science

Background:

• Short bowel syndrome is a critical condition with limited therapeutic options.
• Tissue-engineered intestine (TEI) offers a potential treatment, but donor tissue scarcity is a major hurdle.
• Enteroids, expanded epithelial surrogates, present a viable alternative donor source.

Purpose of the Study:

• To investigate the potential of using enteroids for the production of TEI.
• To evaluate the efficacy of different seeding methods (Matrigel vs. culture medium) for TEI generation.
• To assess the feasibility of using enteroids derived from small intestinal biopsies.

Main Methods:

• Murine crypts were cultured to establish enteroids, which were then seeded onto polymer scaffolds.
• Scaffolds with enteroids were implanted in immunosuppressed mice for 4 weeks to allow TEI development.
• Histological analysis, including PAS staining and immunofluorescence, was performed to assess TEI structure and composition.

Main Results:

• TEI was successfully produced in 15/15 scaffolds when enteroids were seeded in Matrigel, compared to 9/15 in culture medium.
• Matrigel significantly increased neomucosal surface area (10,520 ± 2905 μm) versus medium (450 ± 127 μm).
• Histology confirmed the presence of functional intestinal components, including crypts, epithelial lineages, and myofibroblasts, in the engineered tissue.

Conclusions:

• Enteroids can be generated from minimal tissue samples, expanded ex vivo, and used to create TEI.
• This approach provides a promising solution to overcome the limited availability of donor intestine for TEI production.
• The findings suggest a viable strategy for developing TEI for patients suffering from short bowel syndrome.